Cardio Diagnostics Holdings, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Meeshanthini V. Dogan
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 N Aberdeen St Chicago IL United States of America 60642
- IPO Date
- Jan 14, 2022
- CIK
- 0001870144
- Website
- cdio.ai
- Similar Companies
- Business
- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) develops and commercializes AI-powered epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management. The company offers Epi+Gen CHD, a blood test assessing three-year risk for symptomatic coronary heart disease events including heart attacks; PrecisionCHD, an integrated epigenetic-genetic blood test for coronary heart disease detection; Actionable Clinical Intelligence, a platform providing personalized epigenetic and genetic insights for chronic care management linked to Epi+Gen CHD and PrecisionCHD; Cardiovascular Risk Intelligence, a platform for healthcare stakeholders including providers, employers, brokers, benefits consultants, and government entities; and a research-use-only platform supporting biopharmaceutical discovery, development, and validation for cardiovascular diseases. Founded in 2017 and headquartered in Chicago, Illinois, Cardio Diagnostics operates in the United States, targeting healthcare providers, patients at risk for coronary heart disease, stroke, heart failure, and related comorbidities. Recent developments include partnerships with 15 new provider organizations across Northeast, South, Midwest, and West regions in October 2025 to expand adoption of Epi+Gen CHD and PrecisionCHD; and receipt of final Medicare gapfill payment rates of $854 for both tests from CMS in December 2025, effective January 1, 2026, up from preliminary rates of $350 and $684.76.
Atlas Healthcare Physicians to Cover Cardio Diagnostics' Precision Cardiovascular Medicine Tests Across Its Network
Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO)
Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India
Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community
Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD's Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions
NCH Becomes First U.S. Hospital to Use AI That Detects Hidden Heart Attack Risk a Decade in Advance
Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community
Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States
Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price
Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico
Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session